Pharmaceutical companies just got a choice: play by the administration's rules or watch tariffs destroy your business model.
A company that agrees to Most Favored Nations pricing - charging Americans the same as patients in richer countries - plus commits to domestic manufacturing gets zero tariffs through January 2029. Companies that refuse face 100% tariffs.
Companies that onshore production without price cuts get 20% tariffs. Companies from Europe, Japan, Korea, and Switzerland get 15%.
The system takes effect in 120 days for large manufacturers and 180 days for smaller ones. Building a factory in America costs billions.
A 100% tariff on imported products costs billions faster. For many companies, the choice becomes obvious - negotiate now or negotiate from weakness later.
This only works if pharmaceutical companies believe the administration will enforce these tariffs. If they think this is theater, they'll wait it out.
Orphan drugs - expensive medications for rare diseases - are exempt. That tells you where the administration knows the political limits are.
Watch which companies sign deals first. If Pfizer, Johnson & Johnson, or Merck agree to price cuts and onshoring within 60 days, the system works. If they drag their feet, it collapses.
